Revolution gets selective
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
Another Roche TIGIT disappointment
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
ELCC 2025 – subQ Keytruda heads towards approval
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
AACR 2025 preview – Roche's TIGIT postmortem
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
Pfizer dials down its atirmociclib ambitions
The company is stepping back in second-line breast cancer.
